On September 15, 2025 Limula, a Swiss life sciences tools company advancing automated solutions for cell and gene therapy (CGT) manufacturing reported the collaboration with the Institut Paoli-Calmettes (IPC) to characterise the cell processing capabilities of LimONE for haematopoietic stem cell (HSC) transplantation applications (Press release, Limula, SEP 15, 2025, View Source [SID1234655975]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

IPC is internationally recognised as a leading treatment centre for cell therapies in haematological cancers and runs one of the most established autologous and allogeneic stem cell transplantation programmes in Europe. Performing more than 150 transplants each year, IPC is committed to advancing clinical innovation and broadening patient access to cutting-edge treatments.

The collaboration will leverage Limula’s automated and closed LimONE platform for autologous HSC transplantation, a procedure impacting nearly 50,000 patients annually in Europe. After promising preliminary results using an early prototype of Limula’s technology in 2022, and with strong confirmatory results earlier in 2025, IPC will further document the performance of LimONE. The goal of the collaboration is to advance automated cell product processing, with a focus on the removing of cryoprotectants and cell debris from thawed apheresis products. A fast and efficient wash is critical for maintaining the quality and consistency of the cell product and also significantly improves the patient experience.

"We are impressed with the improvements we saw during the development of LimONE and are eager to adopt the platform into our facility," said Boris Calmels, Head of the Cellular Manufacturing Unit at IPC. "I see strong potential for Limula’s technology to play a key role in improving both our cell processes and the patient’s experience during stem cell transplantation."

Luc Henry, CEO of Limula added: "This collaboration is a powerful demonstration of the versatility of our platform. We are proud to support IPC in their mission to deliver high-quality transplantation products to their patients."